• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SOPHiA GENETICS Announces Nomination of Lila Tretikov to Board of Directors

    5/31/23 9:12:00 AM ET
    $SOPH
    $XYL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Fluid Controls
    Industrials
    Get the next $SOPH alert in real time by email

    Microsoft's Deputy Chief Technology Officer to be appointed at Annual Shareholders' Meeting

    BOSTON and LAUSANNE, Switzerland, May 31, 2023 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the nomination of Lila Tretikov to its Board of Directors. The Board of Directors has proposed the appointment of Tretikov as a member of the board at the Annual General Meeting of Shareholders of SOPHiA GENETICS SA on June 26, 2023.

    Lila Tretikov

    An award-winning powerhouse in the global technology space, Tretikov is currently Deputy Chief Technology Officer at Microsoft, where she previously served as Corporate Vice President in AI. Before joining Microsoft, Tretikov was CEO and Vice Chair of Terrawatt for two years and served as CEO of Wikipedia and Wikimedia.

    "Lila is a tremendous leader in the artificial intelligence (AI) and technology worlds, with robust experience in bringing companies to scale on a global level. As the founder of several technology companies throughout her career, her entrepreneurial spirit combined with her executive leadership skills and comprehensive experience in AI will complement and add depth to our board and help take SOPHiA GENETICS to the next level," said Jurgi Camblong, CEO and Co-Founder of SOPHiA GENETICS.

    Once appointed to the SOPHiA GENETICS Board of Directors, Tretikov will succeed Milton Silva-Craig and join its current members Jurgi Camblong, Troy Cox, Kathy Hibbs, Didier Hirsch, Vincent Ossipow, Tomer Berkovitz and Jean-Michel Cosséry in developing the company's sustainable growth and strategy.

    "Throughout my career, I've focused on finding projects that create outsized socio-economic impact by leveraging cutting-edge technology. Artificial intelligence has the potential to create positive change for humanity, and especially in medicine and biology," said Lila Tretikov. "SOPHiA GENETICS is revolutionizing the healthcare industry and I am looking forward to working with them to help further their mission of democratizing data-driven medicine."

    Tretikov currently serves as a board director for Onfido (a privately-held digital identity tech company). She is also a member of the board of directors of Volvo Cars (NASDAQ:VOLCAR) and Xylem (NYSE:XYL).

    She graduated from the University of California, Berkeley with a degree in Computer Science, Art and Artificial Intelligence, and has completed executive graduate programs at Stanford University and the University of Oxford.

    For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. 

    About SOPHiA GENETICS 

    SOPHiA GENETICS (NASDAQ:SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. Where others see data, we see answers. 

    SOPHiA GENETICS Forward-Looking Statements:

    This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

    SOPHiA GENETICS Logo (PRNewsfoto/SOPHiA GENETICS)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-nomination-of-lila-tretikov-to-board-of-directors-301837860.html

    SOURCE SOPHiA GENETICS

    Get the next $SOPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SOPH
    $XYL

    CompanyDatePrice TargetRatingAnalyst
    Xylem Inc.
    $XYL
    5/30/2025$148.00Overweight
    Analyst
    SOPHiA GENETICS SA
    $SOPH
    12/18/2024$11.00Buy
    Craig Hallum
    Xylem Inc.
    $XYL
    12/12/2024Outperform → Peer Perform
    Wolfe Research
    Xylem Inc.
    $XYL
    12/9/2024$135.00 → $148.00Neutral → Buy
    Citigroup
    Xylem Inc.
    $XYL
    9/3/2024$138.00Buy → Hold
    TD Cowen
    Xylem Inc.
    $XYL
    8/13/2024$165.00Buy
    UBS
    SOPHiA GENETICS SA
    $SOPH
    8/7/2024$10.00 → $5.00Overweight → Equal-Weight
    Morgan Stanley
    SOPHiA GENETICS SA
    $SOPH
    6/27/2024$6.00Buy
    Guggenheim
    More analyst ratings

    $SOPH
    $XYL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tretikov Lila bought $528 worth of shares (4 units at $131.98) and sold $480 worth of shares (4 units at $119.96) (SEC Form 4)

      4 - Xylem Inc. (0001524472) (Issuer)

      12/2/24 4:16:05 PM ET
      $XYL
      Fluid Controls
      Industrials

    $SOPH
    $XYL
    Financials

    Live finance-specific insights

    See more
    • Xylem Inc. Declares Second Quarter Dividend of 40 Cents per Share

      The Board of Directors of Xylem Inc. (NYSE:XYL), has declared a second quarter dividend of $0.40 per share payable on June 26, 2025, to shareholders of record as of May 29, 2025. About Xylem Xylem (XYL) is a Fortune 500 leading global water solutions company that empowers customers and communities to build a more water-secure world. Our 23,000 diverse employees delivered revenue of $8.6 billion in 2024, optimizing water and resource management with innovation and expertise. Join us at www.xylem.com and let's solve water. View source version on businesswire.com: https://www.businesswire.com/news/home/20250514875391/en/ Media Houston Spencer +1 (914) 240-3046 [email protected] Inve

      5/14/25 4:15:00 PM ET
      $XYL
      Fluid Controls
      Industrials
    • SOPHiA GENETICS Reports First Quarter 2025 Results

      BOSTON and ROLLE, Switzerland, May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenue was $17.8 million, up 13% year-over-year or 15% on a constant currency basisGross margin was 68.7% on a reported basis and 75.7% on an adjusted basis, up from 65.9% and 70.5% in the prior year period, respectivelyIFRS net loss increased 27% year-over-year to $17.4 million (including a net foreign excha

      5/6/25 6:45:00 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xylem Reports First Quarter 2025 Results

      Revenue of $2.1 billion, up 2% on a reported and 3% on an organic basis Earnings per share of $0.69, up 10%; $1.03 on an adjusted basis, up 14% Reaffirming full-year 2025 adjusted earnings per share guidance Xylem Inc. (NYSE:XYL), a leading global water solutions company dedicated to solving the world's most challenging water issues, today reported first-quarter 2025 results. The Company delivered total revenue of $2.1 billion, on strong execution and demand, partially offset by foreign exchange headwinds. First-quarter earnings per share were up 10 percent on a reported basis and 14 percent on an adjusted basis. "The team's first-quarter results exceeded expectations, continuing ou

      4/29/25 6:55:00 AM ET
      $XYL
      Fluid Controls
      Industrials

    $SOPH
    $XYL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP & President, WSS Aulick Rodney covered exercise/tax liability with 1,665 shares, decreasing direct ownership by 2% to 74,304 units (SEC Form 4)

      4 - Xylem Inc. (0001524472) (Issuer)

      5/27/25 5:01:02 PM ET
      $XYL
      Fluid Controls
      Industrials
    • Director Yadav Uday was granted 1,300 shares, increasing direct ownership by 18% to 8,626 units (SEC Form 4)

      4 - Xylem Inc. (0001524472) (Issuer)

      5/14/25 4:16:27 PM ET
      $XYL
      Fluid Controls
      Industrials
    • Director Morelli Mark D was granted 1,300 shares, increasing direct ownership by 26% to 6,298 units (SEC Form 4)

      4 - Xylem Inc. (0001524472) (Issuer)

      5/14/25 4:16:14 PM ET
      $XYL
      Fluid Controls
      Industrials

    $SOPH
    $XYL
    Leadership Updates

    Live Leadership Updates

    See more
    • Hayward Appoints Water Industry Powerhouse Ron Keating to Board of Directors

      Hayward Holdings, Inc. (NYSE:HAYW) Board of Directors appointed Ron Keating to serve as its newest independent director, effective immediately. The Hayward Board now comprises 10 directors, nine of whom are independent. "The appointment of Ron Keating to our Board lends direct global operational and financial expertise to Hayward, along with critical expertise in the water industry," said Kevin Holleran, Hayward President, CEO and Director. "Ron's distinguished career and reputation as a decisive leader brings strategic and practical judgement as we continue to execute our growth strategies and deliver value to shareholders." Keating currently serves as president, chief executive officer

      3/20/25 4:30:00 PM ET
      $HAYW
      $XYL
      Industrial Machinery/Components
      Industrials
      Fluid Controls
    • Matthew Pine, President and Chief Executive Officer of Xylem, Joins Trane Technologies Board of Directors

      Trane Technologies (NYSE:TT), a global climate innovator, announced the appointment of Matthew Pine, president and CEO, Xylem Inc. (NYSE:XYL), to its Board of Directors, effective April 1, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250131141202/en/Matthew Pine, President and Chief Executive Officer of Xylem, Joins Trane Technologies Board of Directors (Photo: Business Wire) "Matthew will be a strong addition to our Board of Directors given his global leadership experience and proven track record of transformation in large industrial companies," said Dave Regnery, chair and CEO of Trane Technologies. "His passion for su

      2/6/25 6:31:00 AM ET
      $TT
      $XYL
      Auto Parts:O.E.M.
      Industrials
      Fluid Controls
    • SOPHiA GENETICS Promotes Ross Muken to President and Appoints George Cardoza as Chief Financial Officer

      BOSTON and ROLLE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO. In the newly created role of company President, Ross Muken will oversee SOPHiA GENETICS's global business operations and work even more closely on strategic planning with CEO, Jurgi C

      11/5/24 6:32:00 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SOPH
    $XYL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SOPHiA GENETICS SA

      SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

      11/13/24 3:31:21 PM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by SOPHiA GENETICS SA (Amendment)

      SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)

      2/20/24 4:55:59 PM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Xylem Inc. (Amendment)

      SC 13G/A - Xylem Inc. (0001524472) (Subject)

      2/14/24 11:48:23 AM ET
      $XYL
      Fluid Controls
      Industrials

    $SOPH
    $XYL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Manchester City Puts Smart Water Tech in Play on the Pitch

      Club aims to reuse 100% of stormwater runoff to support sustainable irrigation Manchester City Football Club is using data and analytics for more than performance on the pitch. A champion of water sustainability, the Club is taking its commitment to the next level – introducing digital solutions from its official water technology partner, Xylem (NYSE:XYL), to help capture and reuse rainwater more efficiently. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522922860/en/Manchester City Football Club is teaming up with Xylem to bring smart water management to City Football Academy. With the help of Xylem Vue, the Club is capturi

      5/22/25 4:00:00 AM ET
      $XYL
      Fluid Controls
      Industrials
    • Advanced Technologies Enable Reuse of 18.1 Billion Cubic Meters of Water

      New report shows how utilities and businesses around the world are reusing water, preventing water loss, and creating more water-secure communities Utilities and businesses around the world have reused 18.1 billion cubic meters of water since 2019, enabled by solutions from global water technology leader Xylem (NYSE:XYL), the Company revealed in its most recent Sustainability Report. That volume is enough to meet the annual water needs of more than 350 million people, based on global use estimates.1 Reuse is just one part of a broader effort to increase global water security – alongside the implementation of advanced treatment and digital technologies. Water managers are using the innovat

      5/15/25 8:00:00 AM ET
      $XYL
      Fluid Controls
      Industrials
    • Xylem Inc. Declares Second Quarter Dividend of 40 Cents per Share

      The Board of Directors of Xylem Inc. (NYSE:XYL), has declared a second quarter dividend of $0.40 per share payable on June 26, 2025, to shareholders of record as of May 29, 2025. About Xylem Xylem (XYL) is a Fortune 500 leading global water solutions company that empowers customers and communities to build a more water-secure world. Our 23,000 diverse employees delivered revenue of $8.6 billion in 2024, optimizing water and resource management with innovation and expertise. Join us at www.xylem.com and let's solve water. View source version on businesswire.com: https://www.businesswire.com/news/home/20250514875391/en/ Media Houston Spencer +1 (914) 240-3046 [email protected] Inve

      5/14/25 4:15:00 PM ET
      $XYL
      Fluid Controls
      Industrials

    $SOPH
    $XYL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Analyst initiated coverage on Xylem with a new price target

      Analyst initiated coverage of Xylem with a rating of Overweight and set a new price target of $148.00

      5/30/25 8:42:01 AM ET
      $XYL
      Fluid Controls
      Industrials
    • Craig Hallum initiated coverage on SOPHiA GENETICS SA with a new price target

      Craig Hallum initiated coverage of SOPHiA GENETICS SA with a rating of Buy and set a new price target of $11.00

      12/18/24 7:54:16 AM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xylem downgraded by Wolfe Research

      Wolfe Research downgraded Xylem from Outperform to Peer Perform

      12/12/24 8:31:33 AM ET
      $XYL
      Fluid Controls
      Industrials

    $SOPH
    $XYL
    SEC Filings

    See more
    • SEC Form SD filed by Xylem Inc.

      SD - Xylem Inc. (0001524472) (Filer)

      5/30/25 4:17:05 PM ET
      $XYL
      Fluid Controls
      Industrials
    • SEC Form 144 filed by SOPHiA GENETICS SA

      144 - SOPHiA GENETICS SA (0001840706) (Subject)

      5/19/25 4:21:14 PM ET
      $SOPH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Xylem Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Xylem Inc. (0001524472) (Filer)

      5/16/25 4:19:30 PM ET
      $XYL
      Fluid Controls
      Industrials